How Gut Bacteria Can Alter a Parkinson’s Drug
Levodopa is used to treat Parkinson’s symptoms because the brain can convert it into dopamine, a chemical needed for normal movement. But a swallowed dose must pass through the digestive tract and bloodstream before reaching the brain. Along the way, gut microbes can change some of the drug.
One bacterium studied for this effect is Enterococcus faecalis, which can make an enzyme called tyrosine decarboxylase. The enzyme removes part of levodopa’s chemical structure, turning it into dopamine in the gut. That dopamine is produced outside the brain, where it cannot readily cross the blood–brain barrier—the protective filter that limits what enters brain tissue.
Why the Conversion Matters
Levodopa is commonly taken with carbidopa, a medicine that blocks the body’s own peripheral enzyme from converting levodopa too early. This helps more of the dose remain available to reach the brain. But bacterial tyrosine decarboxylase is different from the human enzyme and can be less susceptible to carbidopa’s inhibition. As a result, microbial conversion may still affect how much levodopa survives its passage through the gut.
The amount converted can vary with a person’s gut microbes and other conditions, so this mechanism is one possible contributor to differences in drug exposure—not a complete explanation for every unpredictable response or worsening of symptoms. Parkinson’s treatment can be affected by many factors, including how quickly the stomach empties and when doses are taken relative to food.
A Drug’s Journey Has More Than One Gate
The practical insight is that a medicine’s dose is not always the same as the amount that reaches its target. Researchers are studying how gut bacteria process levodopa because understanding that first step could eventually help explain some variation in treatment. For now, patients should not change or stop medication based on microbiome claims; dosing decisions belong with their clinician.
